Cancer Family
Digestive System Neoplasm
CI-CAN-00000012Explore in graph →
Non-malignant4,733 active trials43 approved drugs557 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000012Explore in graph →
Clinical trials
22,059 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05520619 | Combination of Tislelizumab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-002)(EC-CRT-002) | active not recruiting | Phase 2 | 114 | Sun Yat-sen UniversityOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT06313190 | Combination of SBRT and Immunotherapy in Small Hepatocellular Carcinoma (HSBRT2402)(HSBRT2402) | recruiting | Phase 2 | 140 | Sun Yat-sen UniversityOTHER | 1 | Nov 18, 2024 |
| clinicaltrials |
| NCT06612281 | Evaluation of Gixam's Performance in a FIT Negative Population | recruiting | Phase 2 | 400 | Jubaan Ltd.INDUSTRY | 1 | Nov 14, 2024 | clinicaltrials |
| NCT06643689 | Tranilast Vs. Steroids to Prevent Esophageal Stricture (TAPES) After Endoscopic Resection for Superficial Neoplasms(TAPES) | not yet recruiting | Phase 2 | 394 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Nov 14, 2024 | clinicaltrials |
| NCT06532799 | TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer(BAH250) | recruiting | Phase 1 / Phase 2 | 75 | Essen BiotechOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT06684600 | Study of Dalpiciclib Isethionate Plus Pyrotinib Maleate in the Treatment of Advanced Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 35 | Peking UniversityOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT06685354 | Sequential T and I With H101 Via HAI for BCLC C Stage HCC: A Prospective Single-Center Single-Arm Pilot Study | not yet recruiting | Phase 2 | 11 | Henan Cancer HospitalOTHER_GOV | 1 | Nov 12, 2024 | clinicaltrials |
| NCT06411600 | Combination Therapy for BRAF-V600E Metastatic CRCm(BRAVE) | recruiting | Phase 2 | 94 | Vall d'Hebron Institute of OncologyOTHER | 1 | Nov 8, 2024 | clinicaltrials |
| NCT06681285 | Cadonilimab Combined With Anlotinib Followed by Radiotherapy in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (CAR-RMEC)(CAR-RMEC) | not yet recruiting | Phase 2 | 51 | Hebei Medical University Fourth HospitalOTHER | 1 | Nov 8, 2024 | clinicaltrials |
| NCT03874026 | Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients(CIFRA) | recruiting | Phase 2 | 34 | National Cancer Institute, NaplesOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT03979131 | Phase II Study of Avelumab Plus Chemotherapy in the Peri-operative Treatment for Patients With Resectable Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC)(MONEO) | active not recruiting | Phase 2 | 40 | Vall d'Hebron Institute of OncologyOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT04898504 | HAI-Floxuridine, or Liver-Tx, Combined With 2nd Line Chemotherapy Versus 2nd Line Chemotherapy Alone for Patients With Colorectal Liver Metastases and Heavy Tumour Burden.(EXCALIBUR1+2) | active not recruiting | Phase 2 | 45 | Oslo University HospitalOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT06341764 | Neo-adjuvant Chemo and Immunotherapy in the Pre-operAtive Treatment of Locally Advanced CholangIOcarciNoma | recruiting | Phase 2 | 38 | National Cancer Institute, NaplesOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT05254171 | Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer(ASPIRE) | recruiting | Phase 2 / Phase 3 | 600 | Panbela Therapeutics, Inc.INDUSTRY | 10 | Nov 6, 2024 | clinicaltrials |
| NCT06530303 | Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer(BAH248) | recruiting | Phase 1 / Phase 2 | 85 | Essen BiotechOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT06675201 | Neoantigen Vaccines in Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 165 | Sichuan UniversityOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT05595473 | A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 with Valganciclovir (VGCV) in Subjects with Hepatocellular Carcinoma | active not recruiting | Phase 1 / Phase 2 | 42 | Rznomics, Inc.OTHER | 1 | Nov 4, 2024 | clinicaltrials |
| NCT06669078 | NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus NALIRIFOX as Conversion Therapy of Locally Advanced Pancreatic Cancer(NALIRIFOX) | not yet recruiting | Phase 2 | 120 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 0 | Nov 1, 2024 | clinicaltrials |
| NCT06389760 | Nimotuzumab Combined With mFOLFIRINOX/GX as Postoperative Adjuvant Therapy in Pancreatic Cancer | recruiting | Phase 2 | 57 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Oct 31, 2024 | clinicaltrials |
| NCT06667050 | CAPOX Plus Sintilimab and Bevacizumab Biosimilar (IBI305) for Neoadjuvant Treatment of Locally Advanced Gastric Cancer | active not recruiting | Phase 2 | 58 | West China HospitalOTHER | 1 | Oct 31, 2024 | clinicaltrials |
| NCT06664996 | Sintilimab Combined SBRT As Neoadjuvant Therapy for Resectable HCC with PVTT | recruiting | Phase 2 | 33 | West China HospitalOTHER | 1 | Oct 30, 2024 | clinicaltrials |
| NCT06665087 | CGA Guided Ultrafractionated RT and First-line Systemic Treatment in Elderly or Frail Patients with MCRC | not yet recruiting | Phase 2 | 110 | Fudan UniversityOTHER | 0 | Oct 30, 2024 | clinicaltrials |
| NCT06666166 | SHR-A1811 Combined with Apatinib in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer | not yet recruiting | Phase 2 | 28 | Yunpeng LiuOTHER | 1 | Oct 30, 2024 | clinicaltrials |
| NCT06662669 | YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer | not yet recruiting | Phase 1 / Phase 2 | 120 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 0 | Oct 29, 2024 | clinicaltrials |
| NCT06662877 | Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment | not yet recruiting | Phase 2 / Phase 3 | 206 | Sun Yat-sen UniversityOTHER | 1 | Oct 29, 2024 | clinicaltrials |
| NCT06663059 | Adebrelimab Neoadjuvant Treatment for Resectable ESCC: 2 vs 4 Cycles Study | recruiting | Phase 2 | 80 | Tang-Du HospitalOTHER | 1 | Oct 29, 2024 | clinicaltrials |
| NCT06652412 | CGA Guided Ultrafractionated RT and Systemic Treatment in Elderly or Frail Patients with Inoperable Localized CRC | not yet recruiting | Phase 2 | 124 | Fudan UniversityOTHER | 0 | Oct 28, 2024 | clinicaltrials |
| NCT06656559 | Endoscopic Retrograde Cholangiopancreatography With Radiofrequency Ablation (ERCP-RFA) Combined With Envafolimab and Surufatinib Sequential Therapy for Unresectable Biliary Tract Carcinoma | not yet recruiting | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Oct 24, 2024 | clinicaltrials |
| NCT06207656 | Study to Evaluate the Efficacy and Safety of Cetuximab in Combination with Encorafenib Plus Binimetinib As Induction Treatment in BRAF V600E Mutated MSS Initially Resectable or Potentially Resectable Advanced Colorectal Cancer(CEBBRA) | recruiting | Phase 2 | 70 | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)OTHER | 1 | Oct 21, 2024 | clinicaltrials |
| NCT05659914 | Olaparib and Durvalumab (MEDI4736) in Patients with Metastatic Pancreatic Cancer and DNA Damage Repair Genes Alterations | active not recruiting | Phase 2 | 40 | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)OTHER | 1 | Oct 18, 2024 | clinicaltrials |
| NCT06648525 | Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICC | not yet recruiting | Phase 2 | 68 | Harbin Medical UniversityOTHER | 1 | Oct 18, 2024 | clinicaltrials |
| NCT04547166 | A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC) | recruiting | Phase 2 / Phase 3 | 568 | Shanghai Henlius BiotechINDUSTRY | 2 | Oct 17, 2024 | clinicaltrials |
| NCT05260385 | To Evaluate KC1036 in the Patients with Advanced Digestive System Tumors | recruiting | Phase 1 / Phase 2 | 133 | Beijing Konruns Pharmaceutical Co., Ltd.INDUSTRY | 1 | Oct 17, 2024 | clinicaltrials |
| NCT06646588 | Fruquintinib in Combination With Tislelizumab Followed by Radiotherapy in Esophageal Squamous Cell Carcinoma(SJZ-RMEEC01) | recruiting | Phase 2 | 67 | Hebei Medical University Fourth HospitalOTHER | 1 | Oct 17, 2024 | clinicaltrials |
| NCT04183712 | Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA | recruiting | Phase 2 | 102 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT05882370 | TIPS Plus Cadonilimab in Advanced HCC with Tumor Thrombosis-associated Portal Hypertension:a Prospective, Single-arm, Phase II Study | recruiting | Phase 2 | 30 | Fei GaoOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT06641453 | CAR-T Cell Therapy Targeting GPC3 in Patients with Advanced GPC3-Positive Hepatocellular Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT05462496 | Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer | recruiting | Phase 2 | 25 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT05620134 | Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer | active not recruiting | Phase 1 / Phase 2 | 263 | Salubris Biotherapeutics IncINDUSTRY | 2 | Oct 15, 2024 | clinicaltrials |
| NCT05440864 | Durvalumab and Tremelimumab in Resectable HCC((NEOTOMA)) | recruiting | Phase 2 | 28 | University Health Network, TorontoOTHER | 3 | Oct 10, 2024 | clinicaltrials |
| NCT06459921 | Efficacy and Safety of Neoadjuvant Sintilimab Plus FLOT Versus Sintilimab Plus SOX Phase II Clinical Trial for Patients With Locally Advanced Gastric Cancer | not yet recruiting | Phase 2 | 200 | Xijing HospitalOTHER | 0 | Oct 10, 2024 | clinicaltrials |
| NCT06184698 | Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer | recruiting | Phase 2 | 173 | Hebei Medical University Fourth HospitalOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT06632522 | Clinical Study of Radiotherapy Combined With Camrelizumab and Apatinib in the Treatment of Liver Cancer Patients . | not yet recruiting | Phase 2 | 46 | Beijing Tsinghua Chang Gung HospitalOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT05628038 | The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer(TORCH-R) | recruiting | Phase 2 | 93 | Fudan UniversityOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT06621095 | Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001) | not yet recruiting | Phase 2 | 104 | RenJi HospitalOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT04117945 | Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer | active not recruiting | Phase 2 | 22 | Academic and Community Cancer Research UnitedOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT05638698 | Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer(TESLA) | active not recruiting | Phase 2 | 24 | University of Kansas Medical CenterOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT02919644 | Vaccination with Autologous Dendritic Cells Loaded with Autologous Tumour Homogenate After Curative Resection for Stage IV Colorectal Cancer.(COREVAX-1) | recruiting | Phase 2 | 19 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03736863 | A Phase II Exploratory Clinical Trial of Multiple Drug Combinations in the Treatment of Advanced Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 147 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04205227 | ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 137 | ENB Therapeutics, IncINDUSTRY | 2 | Sep 19, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Nov 18, 2024source: clinicaltrials